Regentis Biomaterials Ltd. (AMEX: RGNT) Stock Competitors & Peer Comparison
See RGNT's competitors and their performance on the AMEX and across the wider stock market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for RGNT and its AMEX peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| RGNT | $1.96 | +0.51% | 7.8M | -0.08 | -$24.16 | N/A |
| BDX | $156.36 | +2.22% | 56.6B | 11.62 | $13.45 | +2.39% |
| BDXA | $59.24 | -2.24% | 55.9B | 45.70 | $1.30 | +2.39% |
| MDLN | $38.75 | +2.98% | 32.8B | 45.06 | $0.86 | N/A |
| WST | $328.20 | -7.67% | 23.2B | 41.19 | $7.97 | +0.26% |
| HOLX | $76.01 | +0.00% | 17B | 31.54 | $2.41 | N/A |
| COO | $70.31 | +0.11% | 13.7B | 15.42 | $4.56 | N/A |
| BDXB | $48.16 | +1.39% | 13.7B | 7.60 | $6.33 | +2.39% |
| BAX | $22.40 | +3.37% | 11.6B | 10.77 | $2.08 | +0.89% |
| ATR | $132.36 | +2.61% | 8.4B | 23.13 | $5.72 | +1.43% |
Stock Comparison
Becton, Dickinson and Company (NYSE: BDX)
RGNT vs BDX Comparison July 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 7.8M. In comparison, BDX has a market cap of 56.6B. Regarding current trading prices, RGNT is priced at $1.96 on the AMEX, while BDX trades at $156.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.08, whereas BDX's P/E ratio is 11.62. In terms of profitability, RGNT's ROE is N/A, compared to BDX's ROE of +0.05%. Regarding short-term risk, RGNT is more volatile compared to BDX. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check BDX's competition here
Becton, Dickinson and Company (NYSE: BDXA)
RGNT vs BDXA Comparison July 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 7.8M. In comparison, BDXA has a market cap of 55.9B. Regarding current trading prices, RGNT is priced at $1.96 on the AMEX, while BDXA trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.08, whereas BDXA's P/E ratio is 45.70. In terms of profitability, RGNT's ROE is N/A, compared to BDXA's ROE of +0.05%. Regarding short-term risk, RGNT is more volatile compared to BDXA. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check BDXA's competition here
Medline Inc. (NASDAQ: MDLN)
RGNT vs MDLN Comparison July 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 7.8M. In comparison, MDLN has a market cap of 32.8B. Regarding current trading prices, RGNT is priced at $1.96 on the AMEX, while MDLN trades at $38.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.08, whereas MDLN's P/E ratio is 45.06. In terms of profitability, RGNT's ROE is N/A, compared to MDLN's ROE of +0.07%. Regarding short-term risk, RGNT is more volatile compared to MDLN. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check MDLN's competition here
West Pharmaceutical Services, Inc. (NYSE: WST)
RGNT vs WST Comparison July 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 7.8M. In comparison, WST has a market cap of 23.2B. Regarding current trading prices, RGNT is priced at $1.96 on the AMEX, while WST trades at $328.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.08, whereas WST's P/E ratio is 41.19. In terms of profitability, RGNT's ROE is N/A, compared to WST's ROE of +0.19%. Regarding short-term risk, RGNT is less volatile compared to WST. This indicates lower risk in terms of short-term price fluctuations for RGNT.Check WST's competition here
Hologic, Inc. (NASDAQ: HOLX)
RGNT vs HOLX Comparison July 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 7.8M. In comparison, HOLX has a market cap of 17B. Regarding current trading prices, RGNT is priced at $1.96 on the AMEX, while HOLX trades at $76.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.08, whereas HOLX's P/E ratio is 31.54. In terms of profitability, RGNT's ROE is N/A, compared to HOLX's ROE of +0.11%. Regarding short-term risk, RGNT is more volatile compared to HOLX. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check HOLX's competition here
The Cooper Companies, Inc. (NASDAQ: COO)
RGNT vs COO Comparison July 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 7.8M. In comparison, COO has a market cap of 13.7B. Regarding current trading prices, RGNT is priced at $1.96 on the AMEX, while COO trades at $70.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.08, whereas COO's P/E ratio is 15.42. In terms of profitability, RGNT's ROE is N/A, compared to COO's ROE of +0.03%. Regarding short-term risk, RGNT is more volatile compared to COO. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check COO's competition here
Becton, Dickinson and Company (NYSE: BDXB)
RGNT vs BDXB Comparison July 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 7.8M. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, RGNT is priced at $1.96 on the AMEX, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.08, whereas BDXB's P/E ratio is 7.60. In terms of profitability, RGNT's ROE is N/A, compared to BDXB's ROE of +0.05%. Regarding short-term risk, RGNT is more volatile compared to BDXB. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check BDXB's competition here
Baxter International Inc. (NYSE: BAX)
RGNT vs BAX Comparison July 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 7.8M. In comparison, BAX has a market cap of 11.6B. Regarding current trading prices, RGNT is priced at $1.96 on the AMEX, while BAX trades at $22.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.08, whereas BAX's P/E ratio is 10.77. In terms of profitability, RGNT's ROE is N/A, compared to BAX's ROE of -0.16%. Regarding short-term risk, RGNT is more volatile compared to BAX. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check BAX's competition here
AptarGroup, Inc. (NYSE: ATR)
RGNT vs ATR Comparison July 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 7.8M. In comparison, ATR has a market cap of 8.4B. Regarding current trading prices, RGNT is priced at $1.96 on the AMEX, while ATR trades at $132.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.08, whereas ATR's P/E ratio is 23.13. In terms of profitability, RGNT's ROE is N/A, compared to ATR's ROE of +0.14%. Regarding short-term risk, RGNT is more volatile compared to ATR. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check ATR's competition here
Avantor, Inc. (NYSE: AVTR)
RGNT vs AVTR Comparison July 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 7.8M. In comparison, AVTR has a market cap of 7.8B. Regarding current trading prices, RGNT is priced at $1.96 on the AMEX, while AVTR trades at $11.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.08, whereas AVTR's P/E ratio is 13.46. In terms of profitability, RGNT's ROE is N/A, compared to AVTR's ROE of -0.10%. Regarding short-term risk, RGNT is more volatile compared to AVTR. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check AVTR's competition here
Repligen Corporation (NASDAQ: RGEN)
RGNT vs RGEN Comparison July 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 7.8M. In comparison, RGEN has a market cap of 7.4B. Regarding current trading prices, RGNT is priced at $1.96 on the AMEX, while RGEN trades at $131.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.08, whereas RGEN's P/E ratio is 73.31. In terms of profitability, RGNT's ROE is N/A, compared to RGEN's ROE of +0.02%. Regarding short-term risk, RGNT is more volatile compared to RGEN. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check RGEN's competition here
Teleflex Incorporated (NYSE: TFX)
RGNT vs TFX Comparison July 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 7.8M. In comparison, TFX has a market cap of 5.8B. Regarding current trading prices, RGNT is priced at $1.96 on the AMEX, while TFX trades at $132.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.08, whereas TFX's P/E ratio is 12.32. In terms of profitability, RGNT's ROE is N/A, compared to TFX's ROE of -0.28%. Regarding short-term risk, RGNT is more volatile compared to TFX. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check TFX's competition here
Bausch + Lomb Corporation (NYSE: BLCO)
RGNT vs BLCO Comparison July 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 7.8M. In comparison, BLCO has a market cap of 5.8B. Regarding current trading prices, RGNT is priced at $1.96 on the AMEX, while BLCO trades at $16.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.08, whereas BLCO's P/E ratio is 24.88. In terms of profitability, RGNT's ROE is N/A, compared to BLCO's ROE of -0.03%. Regarding short-term risk, RGNT is more volatile compared to BLCO. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check BLCO's competition here
Stevanato Group S.p.A. (NYSE: STVN)
RGNT vs STVN Comparison July 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 7.8M. In comparison, STVN has a market cap of 5.4B. Regarding current trading prices, RGNT is priced at $1.96 on the AMEX, while STVN trades at $19.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.08, whereas STVN's P/E ratio is 31.81. In terms of profitability, RGNT's ROE is N/A, compared to STVN's ROE of +0.10%. Regarding short-term risk, RGNT is more volatile compared to STVN. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check STVN's competition here
Merit Medical Systems, Inc. (NASDAQ: MMSI)
RGNT vs MMSI Comparison July 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 7.8M. In comparison, MMSI has a market cap of 4.4B. Regarding current trading prices, RGNT is priced at $1.96 on the AMEX, while MMSI trades at $74.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.08, whereas MMSI's P/E ratio is 19.01. In terms of profitability, RGNT's ROE is N/A, compared to MMSI's ROE of +0.09%. Regarding short-term risk, RGNT is more volatile compared to MMSI. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check MMSI's competition here
ICU Medical, Inc. (NASDAQ: ICUI)
RGNT vs ICUI Comparison July 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 7.8M. In comparison, ICUI has a market cap of 3.9B. Regarding current trading prices, RGNT is priced at $1.96 on the AMEX, while ICUI trades at $157.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.08, whereas ICUI's P/E ratio is 19.66. In terms of profitability, RGNT's ROE is N/A, compared to ICUI's ROE of +0.02%. Regarding short-term risk, RGNT is more volatile compared to ICUI. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check ICUI's competition here
Haemonetics Corporation (NYSE: HAE)
RGNT vs HAE Comparison July 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 7.8M. In comparison, HAE has a market cap of 3.6B. Regarding current trading prices, RGNT is priced at $1.96 on the AMEX, while HAE trades at $78.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.08, whereas HAE's P/E ratio is 15.86. In terms of profitability, RGNT's ROE is N/A, compared to HAE's ROE of +0.11%. Regarding short-term risk, RGNT is more volatile compared to HAE. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check HAE's competition here
DENTSPLY SIRONA Inc. (NASDAQ: XRAY)
RGNT vs XRAY Comparison July 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 7.8M. In comparison, XRAY has a market cap of 2.6B. Regarding current trading prices, RGNT is priced at $1.96 on the AMEX, while XRAY trades at $12.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.08, whereas XRAY's P/E ratio is 9.04. In terms of profitability, RGNT's ROE is N/A, compared to XRAY's ROE of -0.41%. Regarding short-term risk, RGNT is more volatile compared to XRAY. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check XRAY's competition here
LeMaitre Vascular, Inc. (NASDAQ: LMAT)
RGNT vs LMAT Comparison July 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 7.8M. In comparison, LMAT has a market cap of 2.2B. Regarding current trading prices, RGNT is priced at $1.96 on the AMEX, while LMAT trades at $95.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.08, whereas LMAT's P/E ratio is 37.05. In terms of profitability, RGNT's ROE is N/A, compared to LMAT's ROE of +0.16%. Regarding short-term risk, RGNT is more volatile compared to LMAT. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check LMAT's competition here
Pulse Biosciences, Inc. (NASDAQ: PLSE)
RGNT vs PLSE Comparison July 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 7.8M. In comparison, PLSE has a market cap of 2.1B. Regarding current trading prices, RGNT is priced at $1.96 on the AMEX, while PLSE trades at $30.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.08, whereas PLSE's P/E ratio is -27.48. In terms of profitability, RGNT's ROE is N/A, compared to PLSE's ROE of -0.87%. Regarding short-term risk, RGNT is less volatile compared to PLSE. This indicates lower risk in terms of short-term price fluctuations for RGNT.Check PLSE's competition here
AtriCure, Inc. (NASDAQ: ATRC)
RGNT vs ATRC Comparison July 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 7.8M. In comparison, ATRC has a market cap of 1.8B. Regarding current trading prices, RGNT is priced at $1.96 on the AMEX, while ATRC trades at $35.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.08, whereas ATRC's P/E ratio is 1088.20. In terms of profitability, RGNT's ROE is N/A, compared to ATRC's ROE of +0.02%. Regarding short-term risk, RGNT is less volatile compared to ATRC. This indicates lower risk in terms of short-term price fluctuations for RGNT.Check ATRC's competition here
BioLife Solutions, Inc. (NASDAQ: BLFS)
RGNT vs BLFS Comparison July 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 7.8M. In comparison, BLFS has a market cap of 1.5B. Regarding current trading prices, RGNT is priced at $1.96 on the AMEX, while BLFS trades at $29.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.08, whereas BLFS's P/E ratio is -141.85. In terms of profitability, RGNT's ROE is N/A, compared to BLFS's ROE of -0.03%. Regarding short-term risk, RGNT is more volatile compared to BLFS. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check BLFS's competition here
Azenta, Inc. (NASDAQ: AZTA)
RGNT vs AZTA Comparison July 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 7.8M. In comparison, AZTA has a market cap of 1.3B. Regarding current trading prices, RGNT is priced at $1.96 on the AMEX, while AZTA trades at $27.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.08, whereas AZTA's P/E ratio is 60.82. In terms of profitability, RGNT's ROE is N/A, compared to AZTA's ROE of -0.11%. Regarding short-term risk, RGNT is more volatile compared to AZTA. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check AZTA's competition here
Kestra Medical Technologies, Ltd. (NASDAQ: KMTS)
RGNT vs KMTS Comparison July 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 7.8M. In comparison, KMTS has a market cap of 1.2B. Regarding current trading prices, RGNT is priced at $1.96 on the AMEX, while KMTS trades at $21.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.08, whereas KMTS's P/E ratio is -8.92. In terms of profitability, RGNT's ROE is N/A, compared to KMTS's ROE of -0.59%. Regarding short-term risk, RGNT is more volatile compared to KMTS. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check KMTS's competition here
STAAR Surgical Company (NASDAQ: STAA)
RGNT vs STAA Comparison July 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 7.8M. In comparison, STAA has a market cap of 1.2B. Regarding current trading prices, RGNT is priced at $1.96 on the AMEX, while STAA trades at $23.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.08, whereas STAA's P/E ratio is 41.02. In terms of profitability, RGNT's ROE is N/A, compared to STAA's ROE of -0.06%. Regarding short-term risk, RGNT is more volatile compared to STAA. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check STAA's competition here
QuidelOrtho Corporation (NASDAQ: QDEL)
RGNT vs QDEL Comparison July 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 7.8M. In comparison, QDEL has a market cap of 1.1B. Regarding current trading prices, RGNT is priced at $1.96 on the AMEX, while QDEL trades at $16.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.08, whereas QDEL's P/E ratio is 11.98. In terms of profitability, RGNT's ROE is N/A, compared to QDEL's ROE of -0.56%. Regarding short-term risk, RGNT is more volatile compared to QDEL. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check QDEL's competition here
Atrion Corporation (NASDAQ: ATRI)
RGNT vs ATRI Comparison July 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 7.8M. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, RGNT is priced at $1.96 on the AMEX, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.08, whereas ATRI's P/E ratio is 64.50. In terms of profitability, RGNT's ROE is N/A, compared to ATRI's ROE of +0.08%. Regarding short-term risk, RGNT is more volatile compared to ATRI. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check ATRI's competition here
AngioDynamics, Inc. (NASDAQ: ANGO)
RGNT vs ANGO Comparison July 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 7.8M. In comparison, ANGO has a market cap of 561.7M. Regarding current trading prices, RGNT is priced at $1.96 on the AMEX, while ANGO trades at $13.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.08, whereas ANGO's P/E ratio is -34.85. In terms of profitability, RGNT's ROE is N/A, compared to ANGO's ROE of -0.21%. Regarding short-term risk, RGNT is more volatile compared to ANGO. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check ANGO's competition here
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN)
RGNT vs NNNN Comparison July 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 7.8M. In comparison, NNNN has a market cap of 441.5M. Regarding current trading prices, RGNT is priced at $1.96 on the AMEX, while NNNN trades at $9.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.08, whereas NNNN's P/E ratio is 145.38. In terms of profitability, RGNT's ROE is N/A, compared to NNNN's ROE of +0.27%. Regarding short-term risk, RGNT is more volatile compared to NNNN. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check NNNN's competition here
OraSure Technologies, Inc. (NASDAQ: OSUR)
RGNT vs OSUR Comparison July 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 7.8M. In comparison, OSUR has a market cap of 273.3M. Regarding current trading prices, RGNT is priced at $1.96 on the AMEX, while OSUR trades at $3.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.08, whereas OSUR's P/E ratio is -4.78. In terms of profitability, RGNT's ROE is N/A, compared to OSUR's ROE of -0.21%. Regarding short-term risk, RGNT is more volatile compared to OSUR. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check OSUR's competition here
Sanara MedTech Inc. (NASDAQ: SMTI)
RGNT vs SMTI Comparison July 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 7.8M. In comparison, SMTI has a market cap of 234.2M. Regarding current trading prices, RGNT is priced at $1.96 on the AMEX, while SMTI trades at $25.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.08, whereas SMTI's P/E ratio is -426.00. In terms of profitability, RGNT's ROE is N/A, compared to SMTI's ROE of -2.46%. Regarding short-term risk, RGNT is more volatile compared to SMTI. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check SMTI's competition here
Utah Medical Products, Inc. (NASDAQ: UTMD)
RGNT vs UTMD Comparison July 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 7.8M. In comparison, UTMD has a market cap of 213.8M. Regarding current trading prices, RGNT is priced at $1.96 on the AMEX, while UTMD trades at $67.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.08, whereas UTMD's P/E ratio is 19.86. In terms of profitability, RGNT's ROE is N/A, compared to UTMD's ROE of +0.09%. Regarding short-term risk, RGNT is more volatile compared to UTMD. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check UTMD's competition here
InfuSystem Holdings, Inc. (AMEX: INFU)
RGNT vs INFU Comparison July 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 7.8M. In comparison, INFU has a market cap of 183.9M. Regarding current trading prices, RGNT is priced at $1.96 on the AMEX, while INFU trades at $9.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.08, whereas INFU's P/E ratio is 23.97. In terms of profitability, RGNT's ROE is N/A, compared to INFU's ROE of +0.14%. Regarding short-term risk, RGNT is more volatile compared to INFU. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check INFU's competition here
KORU Medical Systems, Inc. (NASDAQ: KRMD)
RGNT vs KRMD Comparison July 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 7.8M. In comparison, KRMD has a market cap of 175.9M. Regarding current trading prices, RGNT is priced at $1.96 on the AMEX, while KRMD trades at $3.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.08, whereas KRMD's P/E ratio is -95.75. In terms of profitability, RGNT's ROE is N/A, compared to KRMD's ROE of -0.14%. Regarding short-term risk, RGNT is more volatile compared to KRMD. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check KRMD's competition here
Pro-Dex, Inc. (NASDAQ: PDEX)
RGNT vs PDEX Comparison July 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 7.8M. In comparison, PDEX has a market cap of 175.4M. Regarding current trading prices, RGNT is priced at $1.96 on the AMEX, while PDEX trades at $54.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.08, whereas PDEX's P/E ratio is 19.34. In terms of profitability, RGNT's ROE is N/A, compared to PDEX's ROE of +0.29%. Regarding short-term risk, RGNT is more volatile compared to PDEX. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check PDEX's competition here
Microbot Medical Inc. (NASDAQ: MBOT)
RGNT vs MBOT Comparison July 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 7.8M. In comparison, MBOT has a market cap of 77.9M. Regarding current trading prices, RGNT is priced at $1.96 on the AMEX, while MBOT trades at $1.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.08, whereas MBOT's P/E ratio is -6.58. In terms of profitability, RGNT's ROE is N/A, compared to MBOT's ROE of -0.22%. Regarding short-term risk, RGNT is more volatile compared to MBOT. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check MBOT's competition here
Akoya Biosciences, Inc. (NASDAQ: AKYA)
RGNT vs AKYA Comparison July 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 7.8M. In comparison, AKYA has a market cap of 64.4M. Regarding current trading prices, RGNT is priced at $1.96 on the AMEX, while AKYA trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.08, whereas AKYA's P/E ratio is -1.34. In terms of profitability, RGNT's ROE is N/A, compared to AKYA's ROE of -1.80%. Regarding short-term risk, RGNT is more volatile compared to AKYA. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check AKYA's competition here
SkyAI, Inc. (NASDAQ: STSS)
RGNT vs STSS Comparison July 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 7.8M. In comparison, STSS has a market cap of 58.4M. Regarding current trading prices, RGNT is priced at $1.96 on the AMEX, while STSS trades at $1.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.08, whereas STSS's P/E ratio is -0.02. In terms of profitability, RGNT's ROE is N/A, compared to STSS's ROE of -1.66%. Regarding short-term risk, RGNT is less volatile compared to STSS. This indicates lower risk in terms of short-term price fluctuations for RGNT.Check STSS's competition here
Daxor Corporation (NASDAQ: DXR)
RGNT vs DXR Comparison July 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 7.8M. In comparison, DXR has a market cap of 52.7M. Regarding current trading prices, RGNT is priced at $1.96 on the AMEX, while DXR trades at $10.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.08, whereas DXR's P/E ratio is 27.33. In terms of profitability, RGNT's ROE is N/A, compared to DXR's ROE of +0.22%. Regarding short-term risk, RGNT is more volatile compared to DXR. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check DXR's competition here
Singular Genomics Systems, Inc. (NASDAQ: OMIC)
RGNT vs OMIC Comparison July 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 7.8M. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, RGNT is priced at $1.96 on the AMEX, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.08, whereas OMIC's P/E ratio is -0.58. In terms of profitability, RGNT's ROE is N/A, compared to OMIC's ROE of -0.43%. Regarding short-term risk, RGNT is more volatile compared to OMIC. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check OMIC's competition here
GlucoTrack, Inc. (NASDAQ: IGAP)
RGNT vs IGAP Comparison July 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 7.8M. In comparison, IGAP has a market cap of 50.2M. Regarding current trading prices, RGNT is priced at $1.96 on the AMEX, while IGAP trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.08, whereas IGAP's P/E ratio is -10.52. In terms of profitability, RGNT's ROE is N/A, compared to IGAP's ROE of -0.86%. Regarding short-term risk, RGNT is more volatile compared to IGAP. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check IGAP's competition here
Nephros, Inc. (NASDAQ: NEPH)
RGNT vs NEPH Comparison July 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 7.8M. In comparison, NEPH has a market cap of 38.6M. Regarding current trading prices, RGNT is priced at $1.96 on the AMEX, while NEPH trades at $3.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.08, whereas NEPH's P/E ratio is 50.86. In terms of profitability, RGNT's ROE is N/A, compared to NEPH's ROE of +0.08%. Regarding short-term risk, RGNT is less volatile compared to NEPH. This indicates lower risk in terms of short-term price fluctuations for RGNT.Check NEPH's competition here
Milestone Scientific Inc. (AMEX: MLSS)
RGNT vs MLSS Comparison July 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 7.8M. In comparison, MLSS has a market cap of 34.5M. Regarding current trading prices, RGNT is priced at $1.96 on the AMEX, while MLSS trades at $0.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.08, whereas MLSS's P/E ratio is -6.50. In terms of profitability, RGNT's ROE is N/A, compared to MLSS's ROE of -1.66%. Regarding short-term risk, RGNT is less volatile compared to MLSS. This indicates lower risk in terms of short-term price fluctuations for RGNT.Check MLSS's competition here
Precision Optics Corporation, Inc. (NASDAQ: POCI)
RGNT vs POCI Comparison July 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 7.8M. In comparison, POCI has a market cap of 33.8M. Regarding current trading prices, RGNT is priced at $1.96 on the AMEX, while POCI trades at $4.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.08, whereas POCI's P/E ratio is -6.07. In terms of profitability, RGNT's ROE is N/A, compared to POCI's ROE of -0.37%. Regarding short-term risk, RGNT is more volatile compared to POCI. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check POCI's competition here
SmileDirectClub, Inc. (NASDAQ: SDC)
RGNT vs SDC Comparison July 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 7.8M. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, RGNT is priced at $1.96 on the AMEX, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.08, whereas SDC's P/E ratio is -0.03. In terms of profitability, RGNT's ROE is N/A, compared to SDC's ROE of -1.96%. Regarding short-term risk, RGNT is less volatile compared to SDC. This indicates lower risk in terms of short-term price fluctuations for RGNT.Check SDC's competition here
Harvard Bioscience, Inc. (NASDAQ: HBIO)
RGNT vs HBIO Comparison July 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 7.8M. In comparison, HBIO has a market cap of 27.3M. Regarding current trading prices, RGNT is priced at $1.96 on the AMEX, while HBIO trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.08, whereas HBIO's P/E ratio is -16.81. In terms of profitability, RGNT's ROE is N/A, compared to HBIO's ROE of -0.73%. Regarding short-term risk, RGNT is more volatile compared to HBIO. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check HBIO's competition here
Invacare Corporation (NYSE: IVC)
RGNT vs IVC Comparison July 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 7.8M. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, RGNT is priced at $1.96 on the AMEX, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.08, whereas IVC's P/E ratio is -0.79. In terms of profitability, RGNT's ROE is N/A, compared to IVC's ROE of -0.46%. Regarding short-term risk, RGNT is more volatile compared to IVC. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check IVC's competition here
Retractable Technologies, Inc. (AMEX: RVP)
RGNT vs RVP Comparison July 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 7.8M. In comparison, RVP has a market cap of 20.4M. Regarding current trading prices, RGNT is priced at $1.96 on the AMEX, while RVP trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.08, whereas RVP's P/E ratio is -2.06. In terms of profitability, RGNT's ROE is N/A, compared to RVP's ROE of -0.08%. Regarding short-term risk, RGNT is more volatile compared to RVP. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check RVP's competition here
Jin Medical International Ltd. (NASDAQ: ZJYL)
RGNT vs ZJYL Comparison July 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 7.8M. In comparison, ZJYL has a market cap of 16M. Regarding current trading prices, RGNT is priced at $1.96 on the AMEX, while ZJYL trades at $2.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.08, whereas ZJYL's P/E ratio is 12.75. In terms of profitability, RGNT's ROE is N/A, compared to ZJYL's ROE of +0.04%. Regarding short-term risk, RGNT is less volatile compared to ZJYL. This indicates lower risk in terms of short-term price fluctuations for RGNT.Check ZJYL's competition here
Femasys Inc. (NASDAQ: FEMY)
RGNT vs FEMY Comparison July 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 7.8M. In comparison, FEMY has a market cap of 11.2M. Regarding current trading prices, RGNT is priced at $1.96 on the AMEX, while FEMY trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.08, whereas FEMY's P/E ratio is -10.25. In terms of profitability, RGNT's ROE is N/A, compared to FEMY's ROE of -2.58%. Regarding short-term risk, RGNT is less volatile compared to FEMY. This indicates lower risk in terms of short-term price fluctuations for RGNT.Check FEMY's competition here
NanoString Technologies, Inc. (NASDAQ: NSTG)
RGNT vs NSTG Comparison July 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 7.8M. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, RGNT is priced at $1.96 on the AMEX, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.08, whereas NSTG's P/E ratio is -0.03. In terms of profitability, RGNT's ROE is N/A, compared to NSTG's ROE of -1.43%. Regarding short-term risk, RGNT is less volatile compared to NSTG. This indicates lower risk in terms of short-term price fluctuations for RGNT.Check NSTG's competition here
NEXGEL, Inc. (NASDAQ: NXGL)
RGNT vs NXGL Comparison July 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 7.8M. In comparison, NXGL has a market cap of 4M. Regarding current trading prices, RGNT is priced at $1.96 on the AMEX, while NXGL trades at $0.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.08, whereas NXGL's P/E ratio is -1.13. In terms of profitability, RGNT's ROE is N/A, compared to NXGL's ROE of -0.70%. Regarding short-term risk, RGNT is less volatile compared to NXGL. This indicates lower risk in terms of short-term price fluctuations for RGNT.Check NXGL's competition here
Predictive Oncology Inc. (NASDAQ: POAI)
RGNT vs POAI Comparison July 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 7.8M. In comparison, POAI has a market cap of 3.6M. Regarding current trading prices, RGNT is priced at $1.96 on the AMEX, while POAI trades at $4.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.08, whereas POAI's P/E ratio is -0.03. In terms of profitability, RGNT's ROE is N/A, compared to POAI's ROE of -107.05%. Regarding short-term risk, RGNT is less volatile compared to POAI. This indicates lower risk in terms of short-term price fluctuations for RGNT.Check POAI's competition here
Lucyd, Inc (NASDAQ: LUCY)
RGNT vs LUCY Comparison July 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 7.8M. In comparison, LUCY has a market cap of 2.6M. Regarding current trading prices, RGNT is priced at $1.96 on the AMEX, while LUCY trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.08, whereas LUCY's P/E ratio is -0.39. In terms of profitability, RGNT's ROE is N/A, compared to LUCY's ROE of -0.83%. Regarding short-term risk, RGNT is more volatile compared to LUCY. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check LUCY's competition here
Meihua International Medical Technologies Co., Ltd. (NASDAQ: MHUA)
RGNT vs MHUA Comparison July 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 7.8M. In comparison, MHUA has a market cap of 2.4M. Regarding current trading prices, RGNT is priced at $1.96 on the AMEX, while MHUA trades at $7.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.08, whereas MHUA's P/E ratio is 0.25. In terms of profitability, RGNT's ROE is N/A, compared to MHUA's ROE of +0.07%. Regarding short-term risk, RGNT is more volatile compared to MHUA. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check MHUA's competition here
NEXGEL, Inc. (NASDAQ: NXGLW)
RGNT vs NXGLW Comparison July 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 7.8M. In comparison, NXGLW has a market cap of 1.8M. Regarding current trading prices, RGNT is priced at $1.96 on the AMEX, while NXGLW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.08, whereas NXGLW's P/E ratio is -0.06. In terms of profitability, RGNT's ROE is N/A, compared to NXGLW's ROE of -0.70%. Regarding short-term risk, RGNT is more volatile compared to NXGLW. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check NXGLW's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVD)
RGNT vs GMVD Comparison July 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 7.8M. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, RGNT is priced at $1.96 on the AMEX, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.08, whereas GMVD's P/E ratio is -0.01. In terms of profitability, RGNT's ROE is N/A, compared to GMVD's ROE of +2.09%. Regarding short-term risk, RGNT is less volatile compared to GMVD. This indicates lower risk in terms of short-term price fluctuations for RGNT.Check GMVD's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVDW)
RGNT vs GMVDW Comparison July 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 7.8M. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, RGNT is priced at $1.96 on the AMEX, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.08, whereas GMVDW's P/E ratio is N/A. In terms of profitability, RGNT's ROE is N/A, compared to GMVDW's ROE of +2.09%. Regarding short-term risk, RGNT is less volatile compared to GMVDW. This indicates lower risk in terms of short-term price fluctuations for RGNT.Check GMVDW's competition here
Avinger, Inc. (NASDAQ: AVGR)
RGNT vs AVGR Comparison July 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 7.8M. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, RGNT is priced at $1.96 on the AMEX, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.08, whereas AVGR's P/E ratio is -0.05. In terms of profitability, RGNT's ROE is N/A, compared to AVGR's ROE of +17.82%. Regarding short-term risk, RGNT is less volatile compared to AVGR. This indicates lower risk in terms of short-term price fluctuations for RGNT.Check AVGR's competition here
Lucyd, Inc (NASDAQ: LUCYW)
RGNT vs LUCYW Comparison July 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 7.8M. In comparison, LUCYW has a market cap of 296.1K. Regarding current trading prices, RGNT is priced at $1.96 on the AMEX, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.08, whereas LUCYW's P/E ratio is -0.00. In terms of profitability, RGNT's ROE is N/A, compared to LUCYW's ROE of -0.83%. Regarding short-term risk, RGNT is less volatile compared to LUCYW. This indicates lower risk in terms of short-term price fluctuations for RGNT.Check LUCYW's competition here
GlucoTrack, Inc. (NASDAQ: GCTK)
RGNT vs GCTK Comparison July 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 7.8M. In comparison, GCTK has a market cap of 165.2K. Regarding current trading prices, RGNT is priced at $1.96 on the AMEX, while GCTK trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.08, whereas GCTK's P/E ratio is -0.01. In terms of profitability, RGNT's ROE is N/A, compared to GCTK's ROE of -5.82%. Regarding short-term risk, RGNT is less volatile compared to GCTK. This indicates lower risk in terms of short-term price fluctuations for RGNT.Check GCTK's competition here
Apria, Inc. (NASDAQ: APR)
RGNT vs APR Comparison July 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 7.8M. In comparison, APR has a market cap of 0. Regarding current trading prices, RGNT is priced at $1.96 on the AMEX, while APR trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.08, whereas APR's P/E ratio is 22.59. In terms of profitability, RGNT's ROE is N/A, compared to APR's ROE of +9.81%. Regarding short-term risk, RGNT is more volatile compared to APR. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check APR's competition here
IntriCon Corporation (NASDAQ: IIN)
RGNT vs IIN Comparison July 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 7.8M. In comparison, IIN has a market cap of 0. Regarding current trading prices, RGNT is priced at $1.96 on the AMEX, while IIN trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.08, whereas IIN's P/E ratio is 226.45. In terms of profitability, RGNT's ROE is N/A, compared to IIN's ROE of -0.00%. Regarding short-term risk, RGNT is more volatile compared to IIN. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check IIN's competition here
Analogic Corporation (NASDAQ: ALOG)
RGNT vs ALOG Comparison July 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 7.8M. In comparison, ALOG has a market cap of 0. Regarding current trading prices, RGNT is priced at $1.96 on the AMEX, while ALOG trades at $83.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.08, whereas ALOG's P/E ratio is 40.93. In terms of profitability, RGNT's ROE is N/A, compared to ALOG's ROE of -0.15%. Regarding short-term risk, RGNT is more volatile compared to ALOG. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check ALOG's competition here
Antares Pharma, Inc. (NASDAQ: ATRS)
RGNT vs ATRS Comparison July 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 7.8M. In comparison, ATRS has a market cap of 0. Regarding current trading prices, RGNT is priced at $1.96 on the AMEX, while ATRS trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.08, whereas ATRS's P/E ratio is 14.95. In terms of profitability, RGNT's ROE is N/A, compared to ATRS's ROE of +0.31%. Regarding short-term risk, RGNT is more volatile compared to ATRS. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check ATRS's competition here
Invuity, Inc. (NASDAQ: IVTY)
RGNT vs IVTY Comparison July 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 7.8M. In comparison, IVTY has a market cap of 0. Regarding current trading prices, RGNT is priced at $1.96 on the AMEX, while IVTY trades at $7.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.08, whereas IVTY's P/E ratio is -3.80. In terms of profitability, RGNT's ROE is N/A, compared to IVTY's ROE of -2.40%. Regarding short-term risk, RGNT is more volatile compared to IVTY. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check IVTY's competition here
Hill-Rom Holdings, Inc. (NYSE: HRC)
RGNT vs HRC Comparison July 2026
Regentis Biomaterials Ltd. (AMEX: RGNT) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RGNT stands at 7.8M. In comparison, HRC has a market cap of 0. Regarding current trading prices, RGNT is priced at $1.96 on the AMEX, while HRC trades at $155.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RGNT currently has a P/E ratio of -0.08, whereas HRC's P/E ratio is 41.92. In terms of profitability, RGNT's ROE is N/A, compared to HRC's ROE of +0.14%. Regarding short-term risk, RGNT is more volatile compared to HRC. This indicates higher risk in terms of short-term price fluctuations for RGNT.Check HRC's competition here